CANF
Price
$1.10
Change
-$0.02 (-1.79%)
Updated
May 9, 12:11 PM (EDT)
Capitalization
14.94M
OABI
Price
$1.57
Change
+$0.04 (+2.61%)
Updated
May 8 closing price
Capitalization
187.17M
Ad is loading...

CANF vs OABI

Header iconCANF vs OABI Comparison
Open Charts CANF vs OABIBanner chart's image
Can-Fite BioPharma
Price$1.10
Change-$0.02 (-1.79%)
Volume$150
Capitalization14.94M
OmniAb
Price$1.57
Change+$0.04 (+2.61%)
Volume$906.5K
Capitalization187.17M
CANF vs OABI Comparison Chart
Loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CANF vs. OABI commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a StrongBuy and OABI is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (CANF: $1.12 vs. OABI: $1.57)
Brand notoriety: CANF and OABI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 28% vs. OABI: 95%
Market capitalization -- CANF: $14.94M vs. OABI: $187.17M
CANF [@Biotechnology] is valued at $14.94M. OABI’s [@Biotechnology] market capitalization is $187.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 0 FA rating(s) are green whileOABI’s FA Score has 1 green FA rating(s).

  • CANF’s FA Score: 0 green, 5 red.
  • OABI’s FA Score: 1 green, 4 red.
According to our system of comparison, both CANF and OABI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 5 TA indicator(s) are bullish while OABI’s TA Score has 5 bullish TA indicator(s).

  • CANF’s TA Score: 5 bullish, 4 bearish.
  • OABI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, OABI is a better buy in the short-term than CANF.

Price Growth

CANF (@Biotechnology) experienced а +7.21% price change this week, while OABI (@Biotechnology) price change was -11.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.07%. For the same industry, the average monthly price growth was +11.10%, and the average quarterly price growth was -13.37%.

Reported Earning Dates

CANF is expected to report earnings on Apr 14, 2025.

OABI is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (-5.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OABI($187M) has a higher market cap than CANF($14.9M). CANF YTD gains are higher at: -31.385 vs. OABI (-55.650). CANF has higher annual earnings (EBITDA): -7.79M vs. OABI (-58.92M). OABI has more cash in the bank: 59.4M vs. CANF (4.73M). CANF has less debt than OABI: CANF (57K) vs OABI (23.8M). OABI has higher revenues than CANF: OABI (20.4M) vs CANF (667K).
CANFOABICANF / OABI
Capitalization14.9M187M8%
EBITDA-7.79M-58.92M13%
Gain YTD-31.385-55.65056%
P/E RatioN/AN/A-
Revenue667K20.4M3%
Total Cash4.73M59.4M8%
Total Debt57K23.8M0%
FUNDAMENTALS RATINGS
CANF: Fundamental Ratings
CANF
OUTLOOK RATING
1..100
1
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CANFOABI
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
60%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
64%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 11 days ago
66%
Declines
ODDS (%)
Bearish Trend 15 days ago
84%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
65%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HLQVX19.15N/A
N/A
JPMorgan Large Cap Value I
GMVAX15.09N/A
N/A
Goldman Sachs Small/Mid Cap Value A
WGISX14.12N/A
N/A
Wasatch International Select Instl
MUIGX15.53N/A
N/A
Nationwide BNY Mellon Dyn US Core R6
HESAX39.79N/A
N/A
Horizon Defensive Core Advisor

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+1.36%
ALDX - CANF
46%
Loosely correlated
+7.46%
OABI - CANF
30%
Poorly correlated
+2.61%
GBIO - CANF
30%
Poorly correlated
-7.77%
TPST - CANF
27%
Poorly correlated
+6.70%
KYTX - CANF
27%
Poorly correlated
+5.45%
More

OABI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OABI has been loosely correlated with TECH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OABI jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OABI
1D Price
Change %
OABI100%
+2.61%
TECH - OABI
42%
Loosely correlated
+2.11%
ALEC - OABI
38%
Loosely correlated
+1.96%
IMNM - OABI
38%
Loosely correlated
+3.77%
NAUT - OABI
37%
Loosely correlated
+2.09%
VCYT - OABI
37%
Loosely correlated
+1.20%
More